# Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT03850574** · PHASE1,PHASE2 · RECRUITING · sponsor: **Aptose Biosciences Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute
- Refractory AML
- Relapsed Adult AML
- Myelodysplastic Syndrome With Excess Blasts-2
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Tuspetinib
- **DRUG:** Venetoclax Oral Tablet
- **DRUG:** Azacitidine for Intravenous Infusion

## Key facts

- **NCT ID:** NCT03850574
- **Lead sponsor:** Aptose Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-03-11
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03850574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03850574, "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03850574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*